Janoshik Tirzepatide 5 mg (Vial)

Product Details:

• Brand: Janoshik
• Compound: Tirzepatide
• Dosage Strength: 5 mg per vial
• Form: Injectable (lyophilized powder or reconstituted liquid)
• Purpose: Weight loss, appetite suppression, blood sugar regulation
• Administration Route: Subcutaneous injection

How It Works:

Tirzepatide works by activating both GLP-1 and GIP receptors, two hormones involved in regulating insulin secretion, satiety, and glucose metabolism. This dual agonist action helps:

• Lower blood sugar levels
• Reduce appetite and food cravings
• Slow gastric emptying, increasing feelings of fullness
• Promote weight loss by reducing caloric intake and enhancing insulin sensitivity

Its unique mechanism makes it more effective than GLP-1-only medications like semaglutide in clinical studies.

Who Should Use It?

• Adults with type 2 diabetes looking to improve glycemic control
• Overweight or obese individuals seeking pharmaceutical support for fat loss
• Non-diabetic users using it off-label under professional guidance for weight management
• Not suitable for:
  • Type 1 diabetics
  • Pregnant or breastfeeding women
  • Individuals with a personal/family history of medullary thyroid carcinoma or MEN2

Usage Instructions:

• Starting Dose (common off-label or medical guidance):
  • Begin with 2.5 mg once per week, then increase to 5 mg after 4 weeks if well tolerated
• Maintenance Dose: 5–15 mg weekly (5 mg often used for maintenance or initial cycles)
• Injection Site: Subcutaneous (abdomen, thigh, or upper arm)
• Reconstitution (if lyophilized): Mix with sterile water or bacteriostatic water as directed
• Use a sterile syringe, rotate injection sites, and follow aseptic technique

Warnings & Precautions:

• Possible Side Effects:
  • Nausea, vomiting, constipation, diarrhea
  • Fatigue, dizziness, decreased appetite
  • Rare but serious: pancreatitis, gallbladder issues, allergic reactions
• Contraindications:
  • History of thyroid cancer (especially medullary thyroid carcinoma)
  • Personal or family history of multiple endocrine neoplasia syndrome type 2 (MEN2)
• Drug Interactions: May interact with insulin, sulfonylureas, and other diabetes medications
• Medical supervision recommended, especially if used for non-diabetic weight loss

Storage Instructions:

• Before reconstitution (powder form):
  • Store in a cool, dry place at 2–8°C (36–46°F)
  • Protect from light
• After reconstitution (liquid):
  • Store in refrigerator (2–8°C)
  • Use within 14–28 days (depending on diluent and sterility)
• Do not freeze
• Keep out of reach of children and pets
• Discard if discolored, cloudy, or past expiration